Skip to content
DataLookout
Menu

NCT07894029

Effect of Neuromuscular Blocking Agent Use on Video Laryngeal Mask Airway Insertion

StatusNot Yet Recruiting
PhasePhase 4
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Proportion of Patients With Optimal Video LMA Position (Brimacombe-Berry Score 4)
Timeframe: Immediately after video laryngeal mask airway insertion (within 3 minutes of insertion)

Secondary (10)

Oropharyngeal Leak Pressure
Video Laryngeal Mask Airway Insertion Time
First-Attempt Insertion Success Rate
Number of Video Laryngeal Mask Airway Insertion Attempts
Insertion Difficulty Score
Show 5 moreShow less
Hemodynamic Parameters
Airway Pressures
Ventilation Leak Volume
Insertion-Related Airway Complications
Postoperative Complications

Arms and interventions

Rocuronium Group (Group R)Experimental

Patients assigned to this group will receive intravenous propofol (2-2.5 mg/kg), remifentanil (1 mcg/kg), and rocuronium (0.6 mg/kg) during anesthesia induction before video laryngeal mask airway placement. Sugammadex 200 mg IV will be administered at the end of surgery before device removal.

Control Group (Group K)Active comparator

Patients assigned to this group will receive intravenous propofol (2-2.5 mg/kg) and remifentanil (1 mcg/kg) during anesthesia induction without administration of a neuromuscular blocking agent before video laryngeal mask airway placement.

Drugs: Rocuronium, Standard Anesthesia Induction (Propofol and Remifentanil)

Sites

1 site in 1 country

  • Hacettepe University Faculty of Medicine HospitalAnkara, Ankara, Turkey (Türkiye)